There is a growing interest in identifying biomarkers for the early detection of Alzheimer’s disease, even before symptoms appear. Detecting the disease at its asymptomatic stages could potentially delay or prevent its onset. Recent research has pinpointed a new biomarker, miR-519a-3p, a microRNA associated with the regulation of the cellular prion protein (PrPC), which is disrupted in various neurodegenerative conditions, including Alzheimer’s. This discovery raises hope for the development of stable and easily detectable biomarkers in biofluids that could revolutionize early Alzheimer’s diagnosis and treatment. With more than 35 million individuals worldwide affected by Alzheimer’s, innovative approaches like miR-519a-3p offer promise in addressing this pressing public health issue.
MiR-519a-3p holds potential as a diagnostic tool for Alzheimer’s in individuals without symptoms, marking a significant advancement in the field. The molecule’s connection to PrPC levels, which fluctuate as the disease progresses, presents a novel opportunity for early detection. By comparing data across different neurodegenerative diseases, researchers have found miR-519a-3p to be specifically linked to Alzheimer’s, showcasing its promise as a targeted biomarker. The next phase involves validating miR-519a-3p in blood samples from diverse patient groups, a crucial step towards integrating it into clinical Alzheimer’s diagnostics in the future.
Link: https://ibecbarcelona.eu/new-biomarker-to-diagnose-alzheimers-in-asymptomatic-stages/
